<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579914</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1301102</org_study_id>
    <nct_id>NCT03579914</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients</brief_title>
  <official_title>Combined Metoprolol and Remote Ischemic Conditioning in Cardioprotection of Anterior ST-segment Elevation Myocardial Infarction (METRICATION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the myocardial protection effect of intravenous&#xD;
      metoprolol combined with remote ischemic conditioning (RIC) and single treatment before&#xD;
      reperfusion in Chinese patients with anterior STEMI. This study sought to find possible&#xD;
      strategies to further improve myocardial protection in Chinese patients with anterior STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center, randomized controlled study. It is planned to&#xD;
      enroll 1200 patients with anterior STEMI. Immediately after the first medical contact, the&#xD;
      patients who were determined by the investigator to meet the inclusion/exclusion criteria&#xD;
      were randomized through the interactive web response system (IWRS) and received different&#xD;
      pre-reperfusion treatments. The four groups were placebo group, metoprolol group, remote&#xD;
      ischemic conditioning (RIC) group and metoprolol &amp; RIC group. Subsequently, the investigator&#xD;
      conduct diagnosis and treatment according to the patient's specific conditions and check the&#xD;
      serum level of myocardial damage markers (i.e. CK and CK-MB) at the time of admission, 12,&#xD;
      24, 36, 48, 60 hours, respectively. If the patient undergoes PCI treatment, additional&#xD;
      detection of myocardial damage markers immediately after PCI is also required. All patients&#xD;
      were followed for 1 year with an office visit or a telephone call at 1, 3, 6, 9 and 12 months&#xD;
      to evaluate the health status and adverse clinical events of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size</measure>
    <time_frame>60 hours</time_frame>
    <description>Estimating myocardial infarct size by area under CK, CK-MB curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>Composition of death, heart failure, reinfarction, revascularization, malignant ventricular arrhythmias, stroke)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarct size measured by MRI (optional)</measure>
    <time_frame>7 days after AMI</time_frame>
    <description>myocardial infarct size measured by MRI (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint: incidence of severe bradycardia or hypotension</measure>
    <time_frame>24 hours</time_frame>
    <description>Severe bradycardia (heart rate &lt;40bpm) or hypotension (systolic blood pressure &lt;80mmHg)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1206</enrollment>
  <condition>Anterior Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive intravenous placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous metoprolol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intravenous metoprolol injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive RIC treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous metoprolol and RIC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intravenous metoprolol injection and RIC treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous Placebo</intervention_name>
    <description>Patients receive intravenous Placebo (saline) injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Injectable Product</intervention_name>
    <description>Patients receive intravenous Metoprolol injection</description>
    <arm_group_label>Intravenous metoprolol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Romote Ischemic Conditioning (RIC)</intervention_name>
    <description>Patients receive RIC treatment</description>
    <arm_group_label>RIC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Metoprolol &amp; RIC</intervention_name>
    <description>Patients receive Metoprolol &amp; RIC treatment</description>
    <arm_group_label>Intravenous metoprolol and RIC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ages 18 to 80 years;&#xD;
&#xD;
          2. presenting within 12 h of symptoms onset, with anterior STEMI and planned for pPCI;&#xD;
             anterior STEMI was defined as the occurrence of &gt;20 min of chest pain and ST-segment&#xD;
             elevation (&gt;2 mm) in at least 2 contiguous precordial leads;&#xD;
&#xD;
          3. sign informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. systolic blood pressure &lt; 110mmHg;&#xD;
&#xD;
          2. cardiogenic shock or with heart failure symptoms, Killip III~IV;&#xD;
&#xD;
          3. allergic history of metoprolol;&#xD;
&#xD;
          4. history of asthma or the need for bronchodilators;&#xD;
&#xD;
          5. PR interval &gt; 240ms, II~III atrioventricular blockï¼›&#xD;
&#xD;
          6. heart rate &lt; 60 beats/min;&#xD;
&#xD;
          7. unable to consent;&#xD;
&#xD;
          8. pregnancy and lactation women;&#xD;
&#xD;
          9. life expectancy for diseases (i.e. cancer) &lt; 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Univerisity People'Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou medical university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the second affiliated hospital of Dalian medical university</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang military district general hospital of the people's liberation army</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of military medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>Anterior Myocardial Infarction</keyword>
  <keyword>Intravenous Metoprolol</keyword>
  <keyword>RIC</keyword>
  <keyword>Myocardial Protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

